The $125M milestone from Sanofi's Phase 3 CIC trial initiation is already earned and recognized in Q4 2026, providing a significant cash boost. The raised revenue guidance signals confidence in the partnership trajectory. Monitor Sanofi's progress toward the U.S. Phase 3 CIC trial in 2027 and the $225M commercial launch milestone, as well as the mid-2027 manufacturing tech transfer milestone ($75M). The activist campaign has de-escalated (Shah Capital reduced stake and withdrew demands), removing a key overhang.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $9.78entry
- T+1 · 11d ago +10.22%α +9.91% · $10.78
- T+5 · 5d ago −10.43%α −13.72% · $8.76
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Novavax reported Q3 2026 total revenue of $68M, a 3% decline from $70M in Q3 2025, and a GAAP net loss of $31M (improved from a $202M loss a year ago). The company raised its full-year 2026 Adjusted Total Revenue guidance by $145M at the midpoint to $385M-$415M, driven by a $125M milestone earned from Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial initiation. The net loss narrowed sharply due to reduced R&D and SG&A expenses.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $68M, down 3% YoY from $70M
- Product sales $26M, up 91% YoY from $13M
- Licensing, royalties and other revenue $43M, down 25% YoY from $57M
- GAAP net loss $31M, improved from net loss of $202M in Q3 2025
- GAAP diluted EPS $(0.19), improved from $(1.25) in Q3 2025
- Raised full-year 2026 Adjusted Total Revenue guidance to $385M-$415M from $235M-$275M
- Earned $125M milestone from Sanofi for Phase 3 CIC trial initiation in October 2026
- Cash, cash equivalents, marketable securities and restricted cash $627M as of Sep 30, 2026
- Combined R&D and SG&A expense guidance improved to $375M-$395M from $370M-$410M
- Sanofi confirmed intent to initiate U.S. Phase 3 CIC trial in 2027
Financial Impact
Full-year 2026 Adjusted Total Revenue guidance raised by $145M at midpoint to $400M; $125M milestone earned in October; net loss narrowed by $171M YoY
Risk Factors
- Revenue still declining YoY (3% drop) as R&D reimbursement from Sanofi winds down
- Stockholders' deficit widened to $(216.9M) from $(127.8M) at year-end 2025
- Heavy reliance on Sanofi partnership for future milestones and royalties; any delays in Sanofi's clinical or regulatory progress would impact Novavax
- Cash burn continues; cash decreased from $751M to $627M since Dec 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001000694-26-000021 |
| Document: nvax-20261105.htm | 0001000694-26-000021 |
| Document: 0001000694-26-000021-index-headers.html | 0001000694-26-000021 |
| Document: 0001000694-26-000021-index.html | 0001000694-26-000021 |
| Document: 0001000694-26-000021.txt | 0001000694-26-000021 |
| 8-K Data (Synthetic) | 0001000694-26-000021 |
Track record
9 reports on NVAX
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +25.51% at T+20 after the Oct 16, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $10.20 Now $8.06 −20.98% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $9.78 to $8.76 Now $8.06 −17.59% ▼ −10.43% −13.72% vs SPY
- Oct 29, 202618d ago 8-K Bullish 5/10 Entry $10.08 to $10.78 Now $8.06 −20.04% ▲ +6.94% +9.65% vs SPY
- Oct 16, 20264w ago SC 13G Neutral 4/10 Entry $10.82 to $9.40 Now $8.06 −25.51% ▼ −13.12% −12.98% vs SPY
- Oct 16, 20264w ago SC 13D/A Bearish 6/10 Entry $10.82 to $9.40 Now $8.06 +25.51% ▲ +13.12% +12.98% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.74 to $8.14 Now $8.06 +4.13% ▲ +5.17% +3.96% vs SPY
- May 6, 202627w ago 8-K Neutral 4/10 Entry $9.36 to $9.62 Now $8.06 −13.89% ▲ +2.78% +1.65% vs SPY
- Apr 27, 202629w ago DEFA14A Neutral 2/10 Entry $8.07 to $8.03 Now $8.06 −0.12% ▼ −0.50% −0.90% vs SPY
- Feb 26, 202637w ago 8-K Bullish 8/10 Entry $11.19 to $9.99 Now $8.06 −27.97% ▼ −10.72% −9.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers